PacBio Files ITC Patent Infringement Complaint Against Oxford Nanopore
November 02 2016 - 4:00PM
Pacific Biosciences of California, Inc. (Nasdaq:PACB), today
announced that it has filed a complaint with the U.S. International
Trade Commission (the “ITC”) against Oxford Nanopore Technologies
Ltd. and its affiliates. The complaint asserts that Oxford
Nanopore’s MinION and PromethION devices and associated
consumables, reagents, and software, as well as related
commercialization activities by Oxford Nanopore and its affiliates,
infringe one or more claims of U.S. Patent No. 9,404,146 (the “146
Patent”), owned by Pacific Biosciences.
The 146 Patent, entitled “Compositions and methods for nucleic
acid sequencing”, was issued in August of this year and covers
novel methods for sequencing single nucleic acid molecules using
linked double-stranded nucleic acid templates, providing
improved sequencing accuracy.
Pacific Biosciences is asking the ITC to institute an
investigation into the infringement of the 146 Patent by Oxford
Nanopore, and to issue an exclusion order permanently barring
infringing Oxford Nanopore products from entry into the United
States and preventing Oxford Nanopore from advertising and selling
infringing products in the United States.
“As a pioneer in the field of single molecule, long read
sequencing, we have invested hundreds of millions of dollars in
research and development across a broad array of disciplines,
including nanofabrication, physics, organic chemistry, photonics,
optics, molecular biology, engineering, signal processing, high
performance computing, and bioinformatics,” said Dr. Michael W.
Hunkapiller, Chief Executive Officer of Pacific Biosciences. “The
contributions made by our many talented inventors have been
recognized with hundreds of awarded patents relevant to long read
sequencing. We stand firm in our resolve to protect that investment
and our leadership position in the field we have created.”
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de novo
genome assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences’ technology
provides high accuracy, ultra-long reads, uniform coverage, and is
the only DNA sequencing technology that provides the ability to
simultaneously detect epigenetic changes. PacBio® sequencing
systems, including consumables and software, provide a simple,
fast, end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to actions or remedies sought from the ITC,
enforcement of patent rights, and other future events. You should
not place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, changes in
circumstances and other factors that are, in some cases, beyond
Pacific Biosciences’ control and could cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Factors that
could materially affect actual results can be found in Pacific
Biosciences’ most recent filings with the Securities and
Exchange Commission, including Pacific Biosciences’ most recent
reports on Forms 8-K, 10-K and 10-Q, and include those listed under
the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts
Media and Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Sep 2023 to Sep 2024